Manufacturing Issues Are Cause Of Impax NDA Rejection

The FDA’s rejection of Impax Pharmaceuticals’ extended-release capsule Rytary for the treatment of idiopathic Parkinson’s disease points to continuing problems at a California manufacturing site.
Washington Drug Letter